JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Cash from Investing Activities
JW (Cayman) Therapeutics Co Ltd
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Cash from Investing Activities
-¥124.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Cash from Investing Activities
¥2.4B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Investing Activities
-¥1.1B
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Investing Activities
-¥2.1B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Investing Activities
-¥993.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-14%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Investing Activities
-¥943.7m
|
CAGR 3-Years
-233%
|
CAGR 5-Years
-143%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Cash from Investing Activities?
Cash from Investing Activities
-124.1m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Cash from Investing Activities amounts to -124.1m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-23%
Over the last year, the Cash from Investing Activities growth was 0%. The average annual Cash from Investing Activities growth rates for JW (Cayman) Therapeutics Co Ltd have been -11% over the past three years , -23% over the past five years .